{
    "clinical_study": {
        "@rank": "137704", 
        "arm_group": {
            "arm_group_label": "Nestle Impact Advanced Recovery", 
            "arm_group_type": "Experimental", 
            "description": "Nestle Impact Advanced Recovery\n1 dose of Nestle Impact Advanced Recovery orally three times a day"
        }, 
        "brief_summary": {
            "textblock": "Nestle Impact has shown efficacy in multiple surgical trials in relation to improving\n      hospital length of stay and infection rate. 1 dose of Nestle Impact Advanced Recovery will\n      be taken orally three times a day beginning on the morning following stem cell transplant\n      and will continue until the day of hospital discharge."
        }, 
        "brief_title": "Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hodgkin's Lymphoma", 
            "Multiple Myeloma", 
            "Non-Hodgkin's Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients receiving an autologous stem cell transplant using the preparative regimens\n             of BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), Melphalan 140mg/m2, or\n             Melphalan 200mg/m2\n\n          -  Any prior diet or supplement will be allowed.\n\n          -  Age >18 years.\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to Nestle Impact including fish oil."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01699581", 
            "org_study_id": "11-HEM-03-MCC"
        }, 
        "intervention": {
            "arm_group_label": "Nestle Impact Advanced Recovery", 
            "description": "dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.", 
            "intervention_name": "Nestle Impact Advanced Recovery", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hodgkin's Lymphoma", 
            "Multiple Myeloma", 
            "Non-Hodgkin's Lymphoma"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lexington", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40536"
                }, 
                "name": "University of Kentucky, Markey Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant", 
        "overall_official": {
            "affiliation": "Lucille P. Markey Cancer Center at University of Kentucky", 
            "last_name": "Greg Monohan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Hospital length of stay", 
                "safety_issue": "No", 
                "time_frame": "Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge"
            }, 
            {
                "measure": "Days to engraftment", 
                "safety_issue": "No", 
                "time_frame": "Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01699581"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Kentucky", 
            "investigator_full_name": "Greg Monohan", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "University of Kentucky", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Greg Monohan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014", 
        "why_stopped": "Interim analysis"
    }
}